Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
AgomAb is set to raise around $120 million through its IPO to advance its Phase 2b trial of ontunisertib for fibrostenosing Crohn’s disease. Additionally, the Massachusetts biotech plans to use its IPO proceeds to support late-stage studies of GB-0985, an anti-TSLP antibody for severe asthma and COPD.
Read full storyGenerate Biomedicines Inc. has filed for an initial public offering, reflecting strong investor interest in the biotech sector. The company is focused on developing treatments for severe asthma and chronic obstructive pulmonary disease.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.